{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:41:30Z","timestamp":1792478490477,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"This work was supported by Biomedical Research Institute Grant of Pusan National University Hospital and a New Faculty Research Grant of Pusan National University, 2025."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-63297-2","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:06:11Z","timestamp":1784549171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of targeted versus fixed dosing of nafamostat mesylate on filter life in patients undergoing continuous renal replacement therapy"],"prefix":"10.1038","volume":"16","author":[{"given":"Harin","family":"Rhee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Sook","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Young","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"2","key":"63297_CR1","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/0005-2744(81)90023-1","volume":"661","author":"S Fujii","year":"1981","unstructured":"Fujii, S. & Hitomi, Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim. Biophys. Acta. 661 (2), 342\u2013345 (1981).","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"63297_CR2","first-page":"164","volume":"15","author":"Y Hitomi","year":"1985","unstructured":"Hitomi, Y., Ikari, N. & Fujii, S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis 15 (3), 164\u2013168 (1985).","journal-title":"Haemostasis"},{"issue":"2","key":"63297_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0049-3848(94)90008-6","volume":"74","author":"M Uchiba","year":"1994","unstructured":"Uchiba, M., Okajima, K., Abe, H., Okabe, H. & Takatsuki, K. Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity. Thromb. Res. 74 (2), 155\u2013161 (1994).","journal-title":"Thromb. Res."},{"issue":"1","key":"63297_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13054-025-05813-w","volume":"30","author":"C Liu","year":"2025","unstructured":"Liu, C. et al. Nafamostat mesilate as anticoagulant for blood purification: a systematic review and meta-analysis. Crit. Care. 30 (1), 43 (2025).","journal-title":"Crit. Care"},{"issue":"1","key":"63297_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s41100-022-00445-0","volume":"8","author":"M Abe","year":"2022","unstructured":"Abe, M. et al. Results of the 2018 Japan Society for Blood Purification in Critical Care survey: current status and outcomes. Ren. Replace. Ther. 8 (1), 58 (2022).","journal-title":"Ren. Replace. Ther."},{"issue":"4","key":"63297_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.23876\/j.krcp.23.310","volume":"43","author":"T Kim","year":"2024","unstructured":"Kim, T. et al. The role of nafamostat mesylate anticoagulation in continuous kidney replacement therapy for critically ill patients with bleeding tendencies: a retrospective study on patient outcomes and safety. Kidney Res. Clin. Pract. 43 (4), 469\u2013479 (2024).","journal-title":"Kidney Res. Clin. Pract."},{"key":"63297_CR7","doi-asserted-by":"crossref","unstructured":"Section\u00a05: Dialysis Interventions for Treatment of AKI. Kidney Int Suppl. 2012;2(1):89\u2013115. (2011).","DOI":"10.1038\/kisup.2011.35"},{"issue":"52","key":"63297_CR8","doi-asserted-by":"publisher","first-page":"e2392","DOI":"10.1097\/MD.0000000000002392","volume":"94","author":"JY Choi","year":"2015","unstructured":"Choi, J. Y. et al. Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial. Med. (Baltim). 94 (52), e2392 (2015).","journal-title":"Med. (Baltim)."},{"issue":"10","key":"63297_CR9","doi-asserted-by":"publisher","first-page":"e108737","DOI":"10.1371\/journal.pone.0108737","volume":"9","author":"YK Lee","year":"2014","unstructured":"Lee, Y. K., Lee, H. W., Choi, K. H. & Kim, B. S. Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS One. 9 (10), e108737 (2014).","journal-title":"PLoS One"},{"issue":"1","key":"63297_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12882-023-03060-1","volume":"24","author":"S Kameda","year":"2023","unstructured":"Kameda, S. et al. Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study. BMC Nephrol. 24 (1), 12 (2023).","journal-title":"BMC Nephrol."},{"issue":"1","key":"63297_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12882-024-03506-0","volume":"25","author":"S Kameda","year":"2024","unstructured":"Kameda, S. et al. Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study. BMC Nephrol. 25 (1), 69 (2024).","journal-title":"BMC Nephrol."},{"key":"63297_CR12","doi-asserted-by":"crossref","unstructured":"Rewa, O. G. et al. Quality of care and safety measures of acute renal replacement therapy: Workgroup statements from the 22nd acute disease quality initiative (ADQI) consensus conference. J Crit Care. ;54:52\u2009\u2013\u20097. (2019).","DOI":"10.1016\/j.jcrc.2019.07.003"},{"issue":"1","key":"63297_CR13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40001-024-01660-7","volume":"29","author":"D Liu","year":"2024","unstructured":"Liu, D. et al. Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study. Eur. J. Med. Res. 29 (1), 72 (2024).","journal-title":"Eur. J. Med. Res."},{"issue":"3","key":"63297_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/cc9003","volume":"14","author":"M Ostermann","year":"2010","unstructured":"Ostermann, M., Dickie, H., Tovey, L. & Treacher, D. Heparin algorithm for anticoagulation during continuous renal replacement therapy. Crit. Care. 14 (3), 419 (2010).","journal-title":"Crit. Care"},{"issue":"24","key":"63297_CR15","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1161\/01.CIR.103.24.2994","volume":"103","author":"J Hirsh","year":"2001","unstructured":"Hirsh, J., Anand, S. S., Halperin, J. L., Fuster, V. & American Heart, A. Guide to anticoagulant therapy: Heparin: a statement for healthcare professionals from the American Heart Association. Circulation 103 (24), 2994\u20133018 (2001).","journal-title":"Circulation"},{"issue":"7","key":"63297_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent, J. L. et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 22 (7), 707\u2013710 (1996).","journal-title":"Intensive Care Med."},{"issue":"8","key":"63297_CR17","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer, M. et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315 (8), 801\u2013810 (2016).","journal-title":"JAMA"},{"issue":"1","key":"63297_CR18","first-page":"E30","volume":"63","author":"Y Miyatake","year":"2017","unstructured":"Miyatake, Y., Makino, S., Kubota, K., Egi, M. & Mizobuchi, S. Association between Intra-Circuit Activated Clotting Time and Incidence of Bleeding Complications during Continuous Renal Replacement Therapy using Nafamostat Mesilate: a Retrospective Pilot Observational Study. Kobe J. Med. Sci. 63 (1), E30\u2013E6 (2017).","journal-title":"Kobe J. Med. Sci."},{"issue":"5","key":"63297_CR19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s001340050892","volume":"25","author":"ZJ Hu","year":"1999","unstructured":"Hu, Z. J., Iwama, H., Suzuki, R., Kobayashi, S. & Akutsu, I. Time course of activated coagulation time at various sites during continuous haemodiafiltration using nafamostat mesilate. Intensive Care Med. 25 (5), 524\u2013527 (1999).","journal-title":"Intensive Care Med."},{"issue":"4","key":"63297_CR20","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1525-1594.2005.29061.x","volume":"29","author":"H Nakae","year":"2005","unstructured":"Nakae, H. & Tajimi, K. Correlation between serum nafamostat mesilate and activated coagulation time during continuous hemodiafiltration. Artif. Organs. 29 (4), 352\u2013354 (2005).","journal-title":"Artif. Organs"},{"issue":"1","key":"63297_CR21","doi-asserted-by":"publisher","first-page":"44847","DOI":"10.1038\/s41598-025-28308-8","volume":"15","author":"S Lee","year":"2025","unstructured":"Lee, S., Kim, J. & Lee, B. Dose response of nafamostat mesylate for anticoagulation monitoring in pediatric critical care during continuous venovenous hemodiafiltration. Sci. Rep. 15 (1), 44847 (2025).","journal-title":"Sci. Rep."},{"issue":"7","key":"63297_CR22","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3346\/jkms.2011.26.7.945","volume":"26","author":"SJ Han","year":"2011","unstructured":"Han, S. J. et al. Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. J. Korean Med. Sci. 26 (7), 945\u2013950 (2011).","journal-title":"J. Korean Med. Sci."},{"issue":"3","key":"63297_CR23","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1067\/mtc.2002.125638","volume":"124","author":"K Kotani","year":"2002","unstructured":"Kotani, K. et al. Extracorporeal membrane oxygenation with nafamostat mesilate as an anticoagulant for massive pulmonary hemorrhage after living-donor lobar lung transplantation. J. Thorac. Cardiovasc. Surg. 124 (3), 626\u2013627 (2002).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"1","key":"63297_CR24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s12882-024-03745-1","volume":"25","author":"Y Qian","year":"2024","unstructured":"Qian, Y., Wu, W., Wang, M., Wei, Y. & Zhong, M. How do filter types of renal replacement therapy affect survival in critically ill patients? Concerns about adsorption of nafamostat mesylate on AN69 membranes. BMC Nephrol. 25 (1), 314 (2024).","journal-title":"BMC Nephrol."},{"key":"63297_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40560-017-0244-x","volume":"5","author":"T Hirayama","year":"2017","unstructured":"Hirayama, T. et al. AN69ST membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: a retrospective study. J. Intensive Care. 5, 46 (2017).","journal-title":"J. Intensive Care"},{"issue":"1","key":"63297_CR26","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1186\/s12882-025-04520-6","volume":"26","author":"SY Lee","year":"2025","unstructured":"Lee, S. Y. et al. Development of a predictive model for nafamostat mesylate dosing in hemodialysis. BMC Nephrol. 26 (1), 572 (2025).","journal-title":"BMC Nephrol."},{"issue":"6","key":"63297_CR27","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.arcmed.2012.08.012","volume":"43","author":"MM Mehdi","year":"2012","unstructured":"Mehdi, M. M. & Rizvi, S. I. Human plasma paraoxonase 1 (PON1) arylesterase activity during aging: correlation with susceptibility of LDL oxidation. Arch. Med. Res. 43 (6), 438\u2013443 (2012).","journal-title":"Arch. Med. Res."},{"issue":"2","key":"63297_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2133\/dmpk.21.147","volume":"21","author":"S Yamaori","year":"2006","unstructured":"Yamaori, S. et al. Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis. Drug Metab. Pharmacokinet. 21 (2), 147\u2013155 (2006).","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"1","key":"63297_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12882-017-0445-5","volume":"18","author":"M Brain","year":"2017","unstructured":"Brain, M., Winson, E., Roodenburg, O. & McNeil, J. Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis. BMC Nephrol. 18 (1), 69 (2017).","journal-title":"BMC Nephrol."},{"issue":"1","key":"63297_CR30","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1186\/s12882-025-04565-7","volume":"26","author":"P Li","year":"2025","unstructured":"Li, P., Li, M., Yin, W., Zhou, Z. & Zhang, L. Efficacy and safety of regional citrate anticoagulation using calcium-containing replacement solution in different modalities of continuous renal replacement therapy: a randomized controlled trial. BMC Nephrol. 26 (1), 624 (2025).","journal-title":"BMC Nephrol."},{"issue":"4","key":"63297_CR31","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/j.ajkd.2021.01.017","volume":"78","author":"H Rhee","year":"2021","unstructured":"Rhee, H., Berenger, B., Mehta, R. L. & Macedo, E. Regional Citrate Anticoagulation for Continuous Kidney Replacement Therapy With Calcium-Containing Solutions: A Cohort Study. Am. J. Kidney Dis. 78 (4), 550\u20139e1 (2021).","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"63297_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13054-019-2317-9","volume":"23","author":"W Zhang","year":"2019","unstructured":"Zhang, W. et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis. Crit. Care. 23 (1), 22 (2019).","journal-title":"Crit. Care"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-63297-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-63297-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-63297-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:16:03Z","timestamp":1792476963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-63297-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["63297"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-63297-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"22 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Pusan National University IRB Committee (approval number: 2508-017-154), which waived the requirement for informed consent. The study was conducted in accordance with the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"33005"}}